Accurate understanding of tumor characteristics

Information at the molecular level helps medical teams gain a deeper understanding of tumor characteristics.

Each patient’s tumor biology and physical condition may be different.

Personalized analysis, through advanced testing technology, provides medical teams with more information,

helping to explore more suitable health management directions and follow-up plans.

Why is further testing still needed when a diagnosis has already been made?

In traditional oncology, treatment plans are typically tailored to the organ location of the cancer, such as classifications like lung cancer, breast cancer, or colon cancer.

However, even within the same type of cancer, tumors in different patients can exhibit significant differences in biological characteristics, molecular variations, and responses to different treatments.

Personalized tumor analysis and related testing can provide medical teams with more information about tumor behavior and molecular characteristics, helping to gain a more comprehensive understanding of the disease.

This additional molecular-level information helps medical teams make more valuable assessments in overall health management, follow-up planning, and ongoing monitoring.

Personalized Cancer Health Management Plan combines standard oncology care with precision medicine analysis, providing medical teams with more information to assist in developing more individualized health management directions.
In studies of some advanced cancer cases, precision medicine approaches have shown clinically valuable results:
  • Overall Survival extended from 25.8 weeks to 51.7 weeks
  • Progression-Free Survival improved from 12.0 weeks to 22.9 weeks
  • Survival Time in Advanced Patients extended from approximately 6 months to over 15 months
  • Disease Control Rate reached approximately 41% in the studies
Contact Us Now
51.7%
Overall Survival
weeks
22.9%
Progression-Free Survival
weeks
41%
Disease Control
rate
Personalised Cancer Health Management Programme

Cancer-related health management usually involves a combination of clinical evaluation, imaging examinations, pathology reports, and medical guidelines to support decision-making.

Precision medicine technologies can provide additional insights at the molecular and biological level, helping medical teams better understand tumour characteristics and offering valuable references for health management and future planning.

Integrating standard oncology care with molecular insights
Supporting more personalised health management strategies
Helping facilitate discussions with oncology specialists about suitable options
Contact Us Now
Information derived from relevant clinical studies and medical literature. For health education purposes only.

Contact our professional team to learn more about our liquid biopsy services.

What are the potential benefits for you?

It helps identify care options that may be more suitable for your specific cancer characteristics, thus supporting better treatment outcomes; it also helps reduce unnecessary physical burden and side effects caused by unsuitable care plans.

Treatment Strategy May Influence Disease Progression
In some studies involving advanced cancer, precision medicine approaches have shown the potential to extend observed survival time for certain patients and provide additional insights to support treatment decision-making.
Conventional Treatment Strategy
Around 6 Months
Average observed survival time for some advanced-stage patients under standard treatment conditions.
Combined Precision Medicine Approach
15+ Months
In certain patient groups, longer survival periods have been observed when precision medicine strategies are incorporated.
Research Observations of Precision Medicine in Lung Cancer
Molecular testing and genetic analysis can help medical teams better understand tumour characteristics. In some patient groups, these insights may support earlier detection and more informed treatment strategies.
+30%
Increase in Early Detection Potential
Studies suggest that molecular testing technologies may improve early identification rates in some lung cancer patients.
Up to 21 Months
Observed Overall and Progression-Free Survival
Among certain patients with specific genetic mutations, precision-targeted strategies have been associated with longer observed survival periods.
Standard Treatment Approaches May Not Reflect Individual Differences
Even when two patients receive the same diagnosis, their tumours may differ significantly in biological characteristics and genetic profiles.
When treatment decisions are mainly based on average data from large patient populations, the unique features of each individual tumour may not always be fully considered.
Population averages may not fully represent an individual's biological characteristics.
Precision medicine analyses tumour biology at the molecular and genetic levels, providing medical teams with additional insights to better understand tumour behaviour and explore more personalised care strategies.
When Facing Cancer, Gaining More Information Can Be an Important First Step
Through molecular testing and precision medicine analysis, medical teams can better understand tumour characteristics and provide more personalised care directions for patients.
Contact Our Precision Oncology Team
Research Observations in Patients with Advanced Cancer
The following data are derived from clinical research observations, indicating that in some patients with advanced cancer, related treatment strategies may provide additional insights to support clinical decision-making.
41.2%
Disease Control Rate (DCR)
95% Confidence Interval: 24.7%–59.3%
2.7 months
Median Progression-Free Survival (PFS)
Progression-Free Survival
9.9 months
Median Overall Survival (OS)
Overall Survival
Note: Some data include a 95% Confidence Interval (CI).
Research References
Selected clinical research data related to precision medicine in the field of oncology.
2025
Study on the Application of Precision Medicine and Survival Outcomes in Patients with Advanced Cancer
The study reported a median survival of approximately 15.7 months among patients receiving matched targeted therapy, compared with around 5–6 months in those without precision-matched treatment; about 44% of patients showed clinically meaningful improvement.
Clinical significance: When treatment strategies align with tumour biological characteristics, overall survival outcomes may potentially improve.
2022
Clinical Applications of Precision Medicine in Patients with Lung Cancer
Research indicated that molecular testing may increase early detection rates by approximately 30% in certain patients; among those with rare genetic mutations, overall survival after receiving specific targeted therapies reached about 21 months.
Clinical significance: Molecular-level testing provides valuable insights for early identification and treatment strategy selection.
2021
Impact of Precision Medicine on Clinical Outcomes: A Single-Centre Retrospective Study
Observational data showed approximately 23% tumour reduction rate and about 41% disease control rate (Disease Control Rate).
Clinical significance: Incorporating additional tumour biological information into treatment decision-making may help improve disease control outcomes.
2018
Survival Observations of Precision Oncology in Patients with Advanced Cancer
The study reported an overall survival of approximately 52 weeks compared with about 26 weeks in patients without precision-matched treatment; progression-free survival was about 23 weeks versus 12 weeks.
Clinical significance: Precision oncology strategies may be associated with improved survival outcomes in some patients with advanced cancer.
For health education and informational purposes only. Clinical outcomes may vary depending on tumour biology, disease stage, and individual patient factors.

Contact our professional team to learn more about our liquid biopsy services.

What are the potential benefits for you?

It helps identify care options that may be more suitable for your specific cancer characteristics, thus supporting better treatment outcomes; it also helps reduce unnecessary physical burden and side effects caused by unsuitable care plans.

Medical Disclaimer:
The information provided in this article is for educational and reference purposes only and does not constitute medical advice or be used as a substitute for professional medical diagnosis, treatment, or advice. ALWAYS CONSULT ANY QUESTIONS YOU MAY HAVE ABOUT YOUR MEDICAL CONDITION OR MEDICAL PROBLEM THAT YOU HAVE ALWAYS CONSULT YOUR PHYSICIAN OR OTHER QUALIFIED HEALTH PROFESSIONAL. The content of this article is not intended to recommend any specific test, treatment, or medication and should not be construed as such. If you develop symptoms or require medical assistance, please contact a healthcare professional promptly.

Want to learn more?

Contact us now!

Whatsapp us!

Call us!
Tel: 2370 3001

Fill in your information and we will contact you!